Hantz Financial Services, Inc. Galectin Therapeutics Inc Transaction History
Hantz Financial Services, Inc.
- $6.6 Billion
- Q3 2025
A detailed history of Hantz Financial Services, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 2,083 shares of GALT stock, worth $11,456. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,083Holding current value
$11,456% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GALT
# of Institutions
99Shares Held
11.1MCall Options Held
139KPut Options Held
124K-
Vanguard Group Inc Valley Forge, PA2.25MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$8.6 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$6.74 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA633KShares$3.48 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0554KShares$3.05 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $327M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...